



gegründet 1808

Societas physico-medica Erlangensis

Vorstand:

Prof. Dr. med. C. Bogdan
Prof. Dr. Dr. h. c. W. Kalender, PhD
Prof. Dr.-Ing. Dr. rer. med. U. Hoppe
Prof. Dr. med. Dr. h. c. K.-H. Plattig
Prof. Dr. med. T. Pasch



Die Physikalisch-Medizinische Sozietät Erlangen

lädt Sie zu folgendem Vortrag ein:

„Strategic manipulation of the tumor microenvironment for efficient immunotherapy of cancer“

Professor Dr. rer. nat. Günter J. Hämmerling

Tumorimmunology Program, German Cancer Research Center (DKFZ)
E-Mail: hammerling@dkfz.de

Intrinsic resistance of tumors to effector T cell infiltration is a major limitation of cancer immunotherapy. Low T cell infiltrates are predictive of poor prognosis in many human cancers and failure of response to cancer immunotherapy treatment. Targeted activation of the tumor microenvironment may overcome this barrier. Prof. Hämmerling will give an insight into his field of expertise of manipulating the degree of T cell infiltration into tumors genetically or by inflammatory mediators, resulting in more efficient elimination of tumors.

Upon completion of his PhD in chemistry at the Max Planck Institute for Immunobiology in Freiburg in 1971, Günter Hämmerling joined the laboratory of Prof. McDevitt at the Stanford University Medical School, USA, for postdoctoral studies devoted to the functional MHC antigens and immune response genes, which resulted in the description of Ia antigens, known today as MHC class II. In 1974, he joined the laboratory of Prof. Klaus Rajewsky at the Institute for Genetics, University of Cologne, where he introduced monoclonal antibodies for the functional analysis of MHC molecules. Since 1979, Prof. Hämmerling has held the position of Chairman of the Division of Molecular Immunology at the German Cancer Research Center Heidelberg, where the work on MHC molecules was extended to the role in immune tolerance, T cell activation, and tumor immunology.

Günter Hämmerling is a member of the European Molecular Biology Organization EMBL. He served on the Scientific Advisory Boards for the Helmholtz Center for Infection Research HZI, Braunschweig, the German Center for Rheumatology Research DRFZ, Berlin, the World Premier Institutes Japan, and the Executive Board of the Association for Immunotherapy of Cancer CIMT. He was co-founder and president of the European Network of Immunology Institutes ENII, and president of the German Society of Immunology DGfI. He also serves on a number of Editorial Boards of scientific journals. To date, he has authored more than 350 publications in leading scientific journals.

Mittwoch, 10. Juni 2015, 17.15 Uhr

(45 Minuten Vortrag plus Diskussion,

im Anschluß findet die Jahresmitgliederversammlung der PhysicoMedica statt)

Veranstaltungsort:

Seminarraum (1.OG) des Instituts für Klinische Mikrobiologie, Immunologie und Hygiene, Wasserturmstraße 3/5
(Zugang: rückwärtiger Hörsaaleingang gegenüber der Orangerie)

Für Rückfragen wenden Sie sich bitte an:

Prof. Dr. med. Christian Bogdan

Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene
Universitätsklinikum Erlangen, Wasserturmstraße 3-5, D-91054 Erlangen

Telefon: 09131 / 852-2551/-2281 · Fax: 09131 / 852-2573 · E-mail: christian.bogdan@uk-erlangen.de